Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: Molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels

Lasers in Surgery and Medicine

Volumn 44, Issue 10, 2012, Pages 796-804

  Tan, Wenbin ^a   Jia, Wangcun ^a   Sun, Victor ^a,b   Mihm, Martin C ^c   Nelson, J Stuart ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California at Irvine   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

angiogenesis; HIF 1 ; port wine stain; pulsed dye laser; rapamycin; VEGF

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; IMMUNOBLOTTING; LASER COAGULATION; MALE; NONHUMAN; PRIORITY JOURNAL; PULSED DYE LASER; REAL TIME POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKIN BLOOD VESSEL DISORDER; TOPICAL TREATMENT;

EID: 84871754469     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.22101     Document Type: Article

References (76)

1. Mulliken JB, Young AR,. Vascular birthmarks-Hemangiomas and malformations. Philadelphia, PA: W.B. Saunders Co.; 1988.
2. Jacobs AH, Walton RG,. The incidence of birthmarks in the neonate. Pediatrics 1976; 58: 218-222.
3. Pratt AG,. Birthmarks in infants. Arch Dermatol Syphilol 1953; 67: 302-305.
4. Milliken JB, Young AR,. Vascular birthmarks: Hemangiomas and malformations. Philadelphia, PA: W.B. Saunders Co; 1988.
5. Jacobs AH, Walton RG,. The incidence of birthmarks in the neonate. Pediatrics 1976; 58 (2): 218-222.
6. Pratt AG,. Birthmarks in infants. Arch Derm 1967; 67: 302-311.
7. Heller A, Rafman S, Zvagulis I, Pless IB,. Birth-defects and psychosocial adjustment. Am J Dis Child 1985; 139 (3): 257-263.
8. Malm M, Carlberg M,. Port-wine stain-A surgical and psychological problem. Ann Plast Surg 1988; 20 (6): 512-516.
9. Kalick SM,. Toward an interdisciplinary psychology of appearances. Psychiatry 1978; 41 (3): 243-253.
10. Lever WF, Schaumburg-Lever G,. Histopathology of the skin. Philadelphia, PA: J.B. Lippincott Co.; 1990.
11. Geronemus RG, Ashinoff R,. The medical necessity of evaluation and treatment of port-wine stains. J Dermatol Surg Oncol 1991; 17 (1): 76-79.
12. Nelson JS, Milner TE, Anvari B, Tanenbaum BS, Kimel S, Svaasand LO, Jacques SL,. Dynamic epidermal cooling during pulsed laser treatment of port-wine stain: A new methodology with preliminary clinical evaluation. Arch Dermatol 1995; 131 (6): 695-700.
13. Nelson JS, Milner TE, Anvari B, Tanenbaum BS, Svaasand LO, Kimel S,. Dynamic epidermal cooling in conjunction with laser-induced photothermolysis of port wine stain blood vessels. Laser Surg Med 1996; 19 (2): 224-229.
14. Chang CJ, Nelson JS,. Cryogen spray cooling and higher fluence pulsed dye laser treatment improve port-wine stain clearance while minimizing epidermal damage. Dermatol Surg 1999; 25 (10): 767-772.
15. Chang CJ, Kelly KM, van Gemert MJC, Nelson JS,. Comparing the effectiveness of 585-nm vs. 595-nm wavelength pulsed dye laser treatment of port wine stains in conjunction with cryogen spray cooling. Laser Surg Med 2002; 31 (5): 352-358.
16. Chiu CH, Chan HHL, Ho WS, Yeung CK, Nelson JS,. Prospective study of pulsed dye laser in conjunction with cryogen spray cooling for treatment of port wine stains in Chinese patients. Dermatol Surg 2003; 29 (9): 909-915.
17. Waldorf HA, Alster TS, McMillan K, Kauvar ANB, Geronemus RG, Nelson JS,. Effect of dynamic cooling on 585-nm pulsed dye laser treatment of port-wine stain birthmarks. Dermatol Surg 1997; 23 (8): 657-662.
18. Fiskerstrand EJ, Ryggen K, Norvang LT, Svaasand LO,. Clinical effects of dynamic cooling during pulsed laser treatment of port-wine stains. Laser Med Sci 1997; 12 (4): 320-327.
19. Ashinoff R, Geronemus RG,. Flashlamp-pumped pulsed dye laser for port wine stains in infancy; Earlier versus later treatment. J Am Acad Dermatol 1991; 24 (3): 467-472.
20. Nelson JS, Appelbaum J,. Clinical management of port-wine stain in infants and young children using the flashlamp-pulsed dye laser. Clin Pediatr 1990; 29 (9): 503-508.
21. Nelson JS,. Selective photothermolysis and removal of cutaneous vasculopathies and tattoos by pulsed laser. Plast Reconstr Surg 1991; 88 (4): 723-731.
22. van der Horst CMAM, Koster PHL, de Borgie CAJM, Bossuyt PMM, van Gemert MJC,. Effect of the timing of treatment of port-wine stains with the flash-lamp-pumped pulsed dye-laser. New Engl J Med 1998; 338 (15): 1028-1033.
23. Yohn JJ, Huff JC, Aeling JL, Walsh P, Morelli JG,. Lesion size is a factor for determining the rate of port-wine stain clearing following pulsed dye laser treatment in adults. Cutis 1997; 59 (5): 267-270.
24. Katugampola GA, Lanigan SW,. Five years' experience of treating port wine stains with the flashlamp-pumped pulsed dye laser. Brit J Dermatol 1997; 137 (5): 750-754.
25. Jia W, Sun V, Tran N, Choi B, Liu SW, Mihm MC, Jr., Phung TL, Nelson JS,. Long-term blood vessel removal with combined laser and topical rapamycin antiangiogenic therapy: Implications for effective port wine stain treatment. Laser Surg Med 2010; 42 (2): 105-112.
26. Coulon C, Georgiadou M, Roncal C, De Bock K, Langenberg T, Carmeliet P,. From vessel sprouting to normalization: Role of the prolyl hydroxylase domain protein/hypoxia-inducible factor oxygen-sensing machinery. Arterioscler Thromb Vasc Biol 2010; 30 (12): 2331-2336.
27. Fong GH,. Regulation of angiogenesis by oxygen sensing mechanisms. J Mol Med 2009; 87 (6): 549-560.
28. Carmeliet P, Jain RK,. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473 (7347): 298-307.
29. Ferrara N,. VEGF-A: A critical regulator of blood vessel growth. Eur Cytokine Netw 2009; 20 (4): 158-163.
30. Nagy JA, Dvorak AM, Dvorak HF,. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol 2007; 2: 251-275.
31. Karar J, Maity A,. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 2011; 4: 51.
32. Hay N, Sonenberg N,. Upstream and downstream of mTOR. Genes Dev 2004; 18 (16): 1926-1945.
33. Pullen N, Thomas G,. The modular phosphorylation and activation of p70s6k. FEBS Lett 1997; 410 (1): 78-82.
34. Saitoh M, Pullen N, Brennan P, Cantrell D, Dennis PB, Thomas G,. Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. J Biol Chem 2002; 277 (22): 20104-20112.
35. Phung TL, Oble DA, Jia W, Benjamin LE, Mihm MC, Jr., Nelson JS,. Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks. Lasers Surg Med 2008; 40 (1): 1-5.
36. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK,. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nat Med 2002; 8 (2): 128-135.
37. Kwon YS, Hong HS, Kim JC, Shin JS, Son Y,. Inhibitory effect of rapamycin on corneal neovascularization in vitro and in vivo. Invest Ophthalmol Vis Sci 2005; 46 (2): 454-460.
38. Huang S, Bjornsti MA, Houghton PJ,. Rapamycins: Mechanism of action and cellular resistance. Cancer Biol Ther 2003; 2 (3): 222-232.
39. Huang S, Houghton PJ,. Mechanisms of resistance to rapamycins. Drug Resist Updat 2001; 4 (6): 378-391.
40. Saunders RN, Metcalfe MS, Nicholson ML,. Rapamycin in transplantation: A review of the evidence. Kidney Int 2001; 59 (1): 3-16.
41. Guertin DA, Sabatini DM,. Defining the role of mTOR in cancer. Cancer Cell 2007; 12 (1): 9-22.
42. Law BK,. Rapamycin: An anti-cancer immunosuppressant? Crit Rev Oncol Hemat 2005; 56 (1): 47-60.
43. Wienecke R, Fackler I, Linsenmaier U, Mayer K, Licht T, Kretzler M,. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 2006; 48 (3): E27-E29.
44. Herry I, Neukirch C, Debray MP, Mignon F, Crestani B,. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 2007; 18 (1): 76-77.
45. Morton JM, McLean C, Booth SS, Snell GI, Whitford HM,. Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. J Heart Lung Transpl 2008; 27 (4): 462-465.
46. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN,. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. New Engl J Med 2008; 358 (2): 140-151.
47. Yilmaz R, Akoglu H, Yirkpantur A, Kilickap S, Arici M, Altun B, Aki T, Erdem Y, Yasavul U, Turgan C,. A novel immunosuppressive agent, sirolimus, in the treatment of Kaposi's sarcoma in a renal transplant recipient. Ren Fail 2007; 29 (1): 103-105.
48. Zmonarski SC, Boratynska M, Rabczynski J, Kazimierczak K, Klinger M,. Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment. Transpl Proc 2005; 37 (2): 964-966.
49. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G,. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. New Engl J Med 2005; 352 (13): 1317-1323.
50. Ormerod AD, Shah SAA, Copeland P, Omar G, Winfield A,. Treatment of psoriasis with topical sirolimus: Preclinical development and a randomized, double-blind trial. Br J Dermatol 2005; 152 (4): 758-764.
51. Haemel AK, O'Brian AL, Teng JM,. Topical rapamycin a novel approach to facial angiofibromas in tuberous sclerosis. Arch Dermatol 2010; 146 (7): 715-718.
52. Loewe R, Oble DA, Valero T, Zukerberg L, Mihm MC, Jr., Nelson JS,. Stem cell marker upregulation in normal cutaneous vessels following pulsed-dye laser exposure and its abrogation by concurrent rapamycin administration: Implications for treatment of port-wine stain birthmarks. J Cutan Pathol 2010; 37 (Supp. 1): 76-82.
53. Nelson JS, Jia W, Phung TL, Mihm MC, Jr., Observations on enhanced port wine stain blanching induced by combined pulsed dye laser and rapamycin administration. Laser Surg Med 2011; 43 (10): 939-942.
54. Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ,. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR) -dependent signaling. FASEB J 2002; 16 (8): 771-780.
55. Pugh CW, Ratcliffe PJ,. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 2003; 9 (6): 677-684.
56. Semenza GL,. Hypoxia-inducible factors in physiology and medicine. Cell 2012; 148 (3): 399-408.
57. Wang GL, Jiang BH, Rue EA, Semenza GL,. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92 (12): 5510-5514.
58. Wiener CM, Booth G, Semenza GL,. In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem Biophys Res Commun 1996; 225 (2): 485-488.
59. Palmer LA, Semenza GL, Stoler MH, Johns RA,. Hypoxia induces type II NOS gene expression in pulmonary artery endothelial cells via HIF-1. Am J Physiol 1998; 274 (2 Pt 1): L212-219.
60. Bergeron M, Yu AY, Solway KE, Semenza GL, Sharp FR,. Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur J Neurosci 1999; 11 (12): 4159-4170.
61. Pialoux V, Mounier R, Brown AD, Steinback CD, Rawling JM, Poulin MJ,. Relationship between oxidative stress and HIF-1 alpha mRNA during sustained hypoxia in humans. Free Radic Biol Med 2009; 46 (2): 321-326.
62. Land SC, Tee AR,. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007; 282 (28): 20534-20543.
63. Tan W, Jia W, Sun V, Nelson JS,. Rapamycin reverses the process of regeneration and revascularization of photocoagulated blood vessels in an animal model. American Society for Laser Medicine and Surgery Annual Conference. Volume 44. Kissimmee, FL, USA Wiley; 2012. p 39.
64. Chen H, Xiong T, Qu Y, Zhao F, Ferriero D, Mu D,. mTOR activates hypoxia-inducible factor-1alpha and inhibits neuronal apoptosis in the developing rat brain during the early phase after hypoxia-ischemia. Neurosci Lett 2012; 507 (2): 118-123.
65. Sekiguchi Y, Zhang J, Patterson S, Liu L, Hamada C, Tomino Y, Margetts PJ,. Rapamycin inhibits transforming growth factor beta induced peritoneal angiogenesis by blocking the secondary hypoxic response. J Cell Mol Med 2012; 16 (8): 1934-1945.
66. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT,. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22 (20): 7004-7014.
67. Wang W, Jia WD, Xu GL, Wang ZH, Li JS, Ma JL, Ge YS, Xie SX, Yu JH,. Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma. Dig Dis Sci 2009; 54 (10): 2128-2136.
68. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL,. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res 2000; 60 (6): 1541-1545.
69. Koch S, Tugues S, Li X, Gualandi L, Claesson-Welsh L,. Signal transduction by vascular endothelial growth factor receptors. Biochem J 2011; 437 (2): 169-183.
70. Semenza GL,. HIF-1: Using two hands to flip the angiogenic switch. Cancer Metastasis Rev 2000; 19 (1-2): 59-65.
71. Semenza GL,. Vascular responses to hypoxia and ischemia. Arterioscler Thromb Vasc Biol 2010; 30 (4): 648-652.
72. Kilic E, Kilic U, Wang Y, Bassetti CL, Marti HH, Hermann DM,. The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB J 2006; 20 (8): 1185-1187.
73. Vuiblet V, Birembaut P, Francois A, Cordonnier C, Noel LH, Goujon JM, Paraf F, Machet MC, Girardot-Seguin S, Lebranchu Y, Rieu P,. Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor. Nephrol Dial Transplant 2012; 27 (1): 411-416.
74. Mizukami Y, Fujiki K, Duerr EM, Gala M, Jo WS, Zhang X, Chung DC,. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. J Biol Chem 2006; 281 (20): 13957-13963.
75. Medici D, Olsen BR,. Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. PLoS ONE 2012; 7 (8): e42913.
76. Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, Lin MI, Walsh K, Dvorak AM, Briscoe DM, Neeman M, Sessa WC, Dvorak HF, Benjamin LE,. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006; 10 (2): 159-170.